CytoDyn to Present at Wall Street Reporter’s Livestream Event on June 2, 2020 at 12 30 pm ET / 9:30 am PT
VANCOUVER, Washington, June 01, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO
140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, Jacob Lalezari, M.D., CEO
of Quest Clinical Research and Chief Science Officer of CytoDyn, along with a representative of Amarex Clinical Research, the Company’s CRO, will provide a comprehensive business and clinical
trials update. The Wall Street Reporter’s event is scheduled for Tuesday, June 2, 2020 at 12:30 pm ET / 9:30 am PT. The presentation will be approximately 15-20 minutes followed by a Q&A
session of approximately 30-40 minutes.
|Date:||Tuesday, June 2, 2020|
|Time:||12:30 pm ET / 9:30 am PT|
Interested participants are encouraged to login early prior to the start of the event, as the online event has a capacity of 3,000 participants. Please note that there will be no telephone
access; this is a webcast only event. The livestream presentation will be archived for 30 days. For anyone unable to attend, a video will be posted on CytoDyn’s website approximately 24 hours after
the presentation. The conference sponsor provides corporate visibility services to CytoDyn for a fee.
About Coronavirus Disease 2019
CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.
SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.